Immuno-combined treatment versus radio-combined treatment in limited-stage small-cell lung cancer.

ABSTRACT:

Background

Although the approval of immunotherapy in patients with extensive-stage small-cell lung cancer (ES-SCLC) has significantly improved the patient's prognosis, synchronous chemoradiotherapy has always been the standard treatment for limited-stage small-cell lung cancer (LS-SCLC).

Objectives

Immuno-combined and radio-combined therapy in LS-SCLC has been applied in clinical practice, but what is the best for LS-SCLC?

Design

This was a retrospective cohort study.

Methods

Patients with LS-SCLC from January 2019 to December 2023 were retrospectively screened and divided into three groups according to the initial treatment regimen whether included immune-combined and radio-combined treatment. Univariate and multivariate Cox regression were used to analyze the

SUBMITTER: Tong L 

PROVIDER: S-EPMC11660283 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature